Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRAS<sup>G12C</sup> mutation: Preliminary results from a pooled analysis of two phase I studies.
Ying Yuan(Zhejiang Cancer Hospital), Kefeng Ding(Second Affiliated Hospital of Zhejiang University), Zhiye Zhang(Jilin Normal University), Dingzhi Huang(Tianjin Medical University Cancer Institute and Hospital), Zengqing Guo(Fujian Provincial Cancer Hospital), Yi Hu(Union Hospital), Yongdong Jin(Shenzhen University), Nong Yang(Central South University), Xiaorong Dong(The University of Melbourne), Mingfang Zhao(First Hospital of China Medical University), Lian Liu(Qilu Hospital of Shandong University), Meili Sun(Jinan Central Hospital), Dong Hua(Jiangnan University), Dongde Wu(Hubei Cancer Hospital), Yueyin Pan(University of Science and Technology of China), Zhiwu Wang(Tangshan People's Hospital), Cunji Wang(Hunan Academy of Traditional Chinese Medicine), Yanhong Deng(Sun Yat-sen University), Huijuan Wang(Zhengzhou University), Xiangjiao Meng(Shandong First Medical University)
Cited by 10
Related Papers
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
|Clinical Cancer Research|2018|456